Walsh's updated (June 2007) book is on the shelves now. I spent only a
few minutes glancing through it, but noticed quickly that it updates
answers to many questions we've raised here over the past couple of
years. For more details, see the book. I'll buy it when my PC returns.

My glance quickly zeroed in on ADT, since I made a challenging decision
about it 30 months ago and will probably face the same choice again some
year. I was relieved to see it reinforced that choice on both levels in
his section on when to begin ADT. My research then concluded that
post-RP ADT extended our life span by 6-8 months on average, and some
more recent research hints at a possibility of another 6 months in
certain narrow scenarios. Now he says those are not the case. Starting
on page 479 his discussion of his new ADT paradigms shows data proving
ADT adds no survival advantage after surgery, reinforcing his
long-standing inclination that maybe we should wait until we have
symptoms. Whether it's as soon as our surgery heals, at the return of
PSA, when positive scans arise, or at the onset of symptoms, it adds no
survival time. It didn't matter whether it was short ADT, IAD, or years
of it; it's the hormone insensitive PC that kills us, and hormones have
no effect on it. Thus, he muses, why mess up our QOL up with ADT until
our *cancer* is messing up our QOL? I suspect that's why my onc, who
prescribed ADT after my RP, now says it's less often prescribed "just in
case".

Earlier in that chapter he concluded that CAB (combined androgen
blockade) adds no benefit to more basic ADT, as we've seen for some time
now.

I.P.